# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that ownership of the U.S. New Drug Application and Investigat...
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the results from its second Phase III study of tradipitant in ...
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.05 ...
No Shareholder Action Required at This TimeWASHINGTON, May 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" ...
ShareCap calls on the Board to initiate a strategic alternatives process that, among the alternatives, reconsiders Future Pak...
"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Le...